Cinclus Pharma Holding AB logo

Cinclus Pharma Holding AB (J8P)

Market Closed
XSTU XSTU
41.42M Market Cap
- P/E Ratio
- Div Yield
- Volume
- Eps
Previous Close
Day Range
0 0
Year Range
0 0
Want to track J8P and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

J8P is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XSTU (EUR).

J8P Chart

Similar

1RC
Creo Medical Group plc
0.1
-5.41%
7ZT
Hamlet Biopharma AB (publ)
-
-
SG0
Fibrobiologics Inc.
-
-
Precision Biosciences Inc.
-
-
YU1
Conavi Medical Corp.
-
-

Cinclus Pharma Holding AB (J8P) FAQ

What is the stock price today?

The current price is €0.00.

On which exchange is it traded?

Cinclus Pharma Holding AB is listed on XSTU.

What is its stock symbol?

The ticker symbol is J8P.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 41.42M.

Has Cinclus Pharma Holding AB ever had a stock split?

No, there has never been a stock split.

Cinclus Pharma Holding AB Profile

Biotechnology Industry
Healthcare Sector
- CEO
XSTU Exchange
- ISIN
Germany Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Cinclus Pharma Holding AB is a prominent pharmaceutical company with a dedicated focus on creating novel treatments for gastrointestinal diseases. At the heart of its research and development efforts is a pioneering drug candidate designed to combat gastric acid-related disorders, with a special emphasis on gastroesophageal reflux disease (GERD). Cinclus Pharma's mission revolves around improving patient outcomes through the application of innovative research methodologies, aiming to devise effective and safe healthcare solutions. The company's strategic use of advanced drug delivery systems, coupled with a profound understanding of gastric acid pathology, positions it as a leader in the development of effective treatment options. This approach not only places Cinclus Pharma at the vanguard of fulfilling unmet medical needs in gastrointestinal health but also underscores its pivotal role in the pharmaceutical industry, aiming to considerably enhance the quality of life for patients worldwide.

Products and Services

  • Drug Candidate for Gastroesophageal Reflux Disease (GERD)

    This flagship product represents Cinclus Pharma's dedication to addressing gastric acid-related disorders, particularly GERD. Employing a blend of cutting-edge research and development strategies, the drug candidate is being designed to offer a superior therapeutic alternative for patients suffering from this condition. By focusing on innovative drug delivery systems and a thorough understanding of the underlying pathology of gastric acid disturbances, Cinclus Pharma aims to provide a solution that not only alleviates symptoms but also contributes to the overall well-being of patients.

Contact Information

Address: -
Phone: -